Back to results
US 9,314,515 B2Granted
Targeted treatment for patients with estrogen receptor negative and progesterone receptor negative breast cancers
AssigneeLudwig Institute for Cancer Research
InventorsAnita Grigoriadis, Otavia L. Caballero, Andrew John George Simpson
Life of this patent
Estimating the term…
Abstract
Treatments for estrogen receptor and progesterone receptor negative breast cancer or estrogen receptor, progesterone receptor and c-erbB2 negative (triple negative) breast cancer are provided.
Claims18
A method for treating breast cancer, comprising
- (i) determining the expression of estrogen receptor (ER) and progesterone receptor (PR) in cells of a breast tumor obtained from a subject, and
- (ii) administering to the subject having the breast tumor that is estrogen receptor and progesterone receptor negative (ER/PR-negative) an amount of one or more of a MAGE antigen protein, a CTAG1b antigen protein, or a CTAG2 antigen protein or one or more immunogenic peptides of a MAGE antigen protein, a CTAG1b antigen protein, or a CTAG2 antigen protein, wherein the breast tumor expresses one or more of the MAGE antigen protein, the CTAG 1b antigen protein, or the CTAG2 antigen protein and the amount is effective to induce or increase an immune response against the one or more proteins and/or peptides.
Dependencies are inferred from the claim text.